These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 19473639

  • 1. Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis.
    Trachsler J, Glück Z, Dickenmann M, Gauthier T, Brünisholz M, Martin PY, Burnier M, Wahl C, Wüthrich RP.
    Clin Nephrol; 2009 Jun; 71(6):697-702. PubMed ID: 19473639
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 5. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
    Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M.
    Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136
    [Abstract] [Full Text] [Related]

  • 6. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study.
    Disney A, Jersey PD, Kirkland G, Mantha M, Charlesworth JA, Gallagher M, Harris D, Gock H, Mangos GJ, Macmillan J, Liu W, Viswalingam A.
    Nephrology (Carlton); 2007 Feb; 12(1):95-101. PubMed ID: 17295668
    [Abstract] [Full Text] [Related]

  • 7. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
    Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C.
    Am J Geriatr Pharmacother; 2008 Jun; 6(2):49-60. PubMed ID: 18675764
    [Abstract] [Full Text] [Related]

  • 8. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009 Dec; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 10. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Dec; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 11. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Dec; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 12. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 15. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [Abstract] [Full Text] [Related]

  • 18. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA, Barcia J, Benador N, Jankauskiene A, Olson K, Podracka L, Shavkin A, Srivaths P, Wong CJ, Petersen J.
    Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
    [Abstract] [Full Text] [Related]

  • 19. Extended dosing of darbepoetin alfa in peritoneal dialysis patients.
    Feriani M, De Meester JM, McMahon LP, Rottembourg JB, Bridges I, Farouk M, Pronai W.
    BMC Nephrol; 2011 Mar 24; 12():13. PubMed ID: 21435267
    [Abstract] [Full Text] [Related]

  • 20. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M, Navarro MJ, de Gracia C, Alvarez G, de Alarcon R, Garcia MA.
    Ren Fail; 2008 Mar 24; 30(8):778-83. PubMed ID: 18791951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.